Pfizer receives European approval to expand use of XALKORI® (crizotinib)
Pfizer announced the EC has approved a label update to expand use of XALKORI® (crizotinib) to first-line treatment of adults with anaplastic lymphoma kinase-positive advanced NSCLC. The Summary of Product Characteristics also has been updated to include efficacy data from PROFILE 1014. November 25, 2015